References
- Stark B, Andreae F, Mosgoeller W, Edetsberger M, Gaubitzer E, Koehler G, Prassl R. (2008). Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur J Pharm Biopharm, 70:153–164.
- Sethi V, Onyüksel H, Rubinstein I. (2005). Liposomal vasoactive intestinal peptide. Methods Enzymol, 391:377–395.
- Stark B, Debbage P, Andreae F, Mosgoeller W, Prassl R. (2007). Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. Biochim Biophys Acta, 1768:705–714.
- Dogrukol-Ak D, Banks WA, Tuncel N, Tuncel M. (2003). Passage of vasoactive intestinal peptide across the blood-brain barrier. Peptides, 24:437–444.
- Brenneman DE, Glazner G, Hill JM, Hauser J, Davidson A, Gozes I. (1998). VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Ann N Y Acad Sci, 865:207–212.
- Dufes C, Gaillard F, Uchegbu IF, Schätzlein AG, Olivier JC, Muller JM. (2004). Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm, 285:77–85.